151 related articles for article (PubMed ID: 26181246)
1. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
Gangadhar TC; Schuchter LM
JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
4. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
5. Skin cancer. Golden age of melanoma therapy.
Hutchinson L
Nat Rev Clin Oncol; 2015 Jan; 12(1):1. PubMed ID: 25511188
[No Abstract] [Full Text] [Related]
6. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
7. Melanoma: immune checkpoint blockade story gets better.
Bhatia S; Thompson JA
Lancet; 2014 Sep; 384(9948):1078-9. PubMed ID: 25034863
[No Abstract] [Full Text] [Related]
8. Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
Riley JL
N Engl J Med; 2013 Jul; 369(2):187-9. PubMed ID: 23724866
[No Abstract] [Full Text] [Related]
9. Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
[No Abstract] [Full Text] [Related]
10. Skin cancer: less is as good as more in refractory melanoma.
Hutchinson L
Nat Rev Clin Oncol; 2014 Sep; 11(9):502. PubMed ID: 25091612
[No Abstract] [Full Text] [Related]
11. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
12. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma.
Weyand AC; Mody RJ; Rabah RM; Opipari VP
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28675691
[TBL] [Abstract][Full Text] [Related]
14. From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.
Razzak M
Nat Rev Clin Oncol; 2013 Jul; 10(7):365. PubMed ID: 23752732
[No Abstract] [Full Text] [Related]
15. Separating Response of Tumor and non-Tumor Cells to Drug
Kleinpoppen M; Moebius C; Grupp K; Kluwe L; Blessmann M
Anticancer Res; 2019 Apr; 39(4):1777-1783. PubMed ID: 30952717
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
19. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
